[_OS8] 一般口演8
骨髄増殖性疾患/MDS/JMML

[OS8-1-4] JMML症例のアザシチジン使用実態に関する後方視的研究
A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia: A report from the JCCG JMML committee

Yuko Honda¹, Yuka Nanjo², Shinsuke Hirabayashi³, Toru Meguro⁴, Nao Yoshida⁵, Hideki Muramatsu⁶, Harumi Kakuda⁷, Shuichi Ozono⁸, Hiroshi Moritake⁹, Masahiro Yasui¹⁰, Hideki Sano¹¹, Atsushi Manabe³, Kazuo Sakashita¹² (1.Department of Pediatrics, University of Occupational and Environmental Health, Japan, 2.Department of Hematology and Oncology, Miyagi Children’s Hospital, Miyagi, Japan, 3.Department of Pediatrics, St Luke’s International Hospital, Tokyo, Japan, 4.Yamagata University Faculty of Medicine, Department of Pediatrics, Yamagata, Japan, 5.Department of Pediatric Hematology and Oncology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 6.Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan, 7.Department of Hematology and Oncology, Chiba Children’s Hospital, Chiba, Japan, 8.Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan, 9.Division of Pediatrics Faculty of Medicine, University of Miyazaki, Miyazaki, Japan, 10.Department of Hematology and Oncology, Osaka Women’s and Children’s Hospital, Osaka, Japan, 11.Fukushima Medical University Hospital, Department of Pediatric Oncology, Fukushima, Japan, 12.Nagano Children’s Hospital, Department of Hematology and Oncology, Nagano, Japan)